共 39 条
[1]
Baker CW(2019)DRCR retina network. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial JAMA. 231 1880-94
[2]
Glassman AR(2015)Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy:a randomized clinical trial JAMA. 314 2137-46
[3]
Beaulieu WT(2017)Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial Lancet. 389 2193-203
[4]
Antoszyk AN(2018)Diabetic retinopathy clinical research network. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial JAMA Opthalmol 136 1138-48
[5]
Browning DJ(2016)Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial Ophthalmology. 123 1351-9
[6]
Chalam KV(2018)Ranibizumab induces regression of diabetic retinopathy in most patients at high risk of progression to proliferative diabetic retinopathy Ophthalmol Retin 2 997-1009
[7]
Sivaprasad S(2014)Fundus workshop of Chinese Ophthalmological Society Chin J Ophthalmol. 50 851-65
[8]
Prevost AT(2018)Mechanistic evaluation of panretinal photocoagulation versus aflibercept in proliferative diabetic retinopathy: CLARITY substudy Investig Ophthalmol Vis Sci. 59 4277-84
[9]
Vasconcelos JC(2019)The rational use of anti-vegf drugs to assist the treatment of diabetic retinopathy Chin J Ophthalmol. 55 565-8
[10]
Riddell A(undefined)undefined undefined undefined undefined-undefined